Malignant Glioma — Trials

Malignant Glioma — Trials · CancerIndex

Clinical trials

Registered studies

2,053 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 589
Recruiting: 314
Ph III recruiting: 16
Growth YoY: +38.9%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (325)

clinicaltrialsPublishedShowing 351–355 of 355 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00481455	Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)	completed	Phase 2	15	CASI pharmaceuticals, Inc.INDUSTRY	1	Nov 25, 2008	clinicaltrials
NCT00250887	Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research	completed	Phase 2	22	University of ZurichOTHER	1	Oct 23, 2007